QPPV.COM KNOWLEDGE ASSESSMENT

Marstacimab: Classification, Mechanism, Haemophilia Use and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Marstacimab: Classification, Mechanism, Haemophilia Use and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient receiving marstacimab develops a venous thromboembolism after surgery and several days of intensive factor replacement. Which interpretation is most appropriate?
Question 2 of 10 Why should intensive rescue treatment be reconstructed when evaluating a thrombosis occurring during marstacimab therapy?
Question 3 of 10 Which analytical approach is most appropriate for aggregate review of thrombotic events with marstacimab?
Question 4 of 10 Why can TFPI inhibition partially compensate for haemophilia A or B?
Question 5 of 10 Which statement best expresses why a simple replacement-factor laboratory level is not sufficient to monitor the operational safety of marstacimab therapy?
Question 6 of 10 Which information is particularly important in a perioperative marstacimab case?
Question 7 of 10 An emergency department is treating acute bleeding in a patient receiving marstacimab. What medication-safety control is most important?
Question 8 of 10 A breakthrough bleed occurs in a patient receiving marstacimab. Which is the most appropriate initial pharmacovigilance interpretation?
Question 9 of 10 How should expected local injection-site reactions be distinguished from hypersensitivity in case processing?
Question 10 of 10 Which statement best describes the significance of regional regulatory differences for pharmacovigilance?

Select an answer to continue.

QPPV.com